logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm has successfully dosed first participant in clinical trial for osteoarthritis

The commencement of participant dosing follows ethics approval.

1509339436_knee.jpg
Paradigm's shares have added 9.5% to $0.405 today

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has now dosed the first participant in the Phase 2b clinical trial at Emeritus Research in Malvern East, Victoria.

The research is undertaking a randomised, double-blind, placebo-controlled Phase 2b clinical trial investigating the drug pentosan polysulfate sodium (PPS) vs placebo in people with knee osteoarthritis and concurrent bone marrow lesions.

One hundred participants will be recruited across five trial sites in Queensland, South Australia, Victoria, and Western Australia with results anticipated in the March quarter of 2019.

The importance of the trials

Osteoarthritis is a condition with a significant unmet medical need.

An injectable PPS has the potential to be a break-through in treatment, as current therapies do not have adequate pain-relieving effects and provide no protection for the degenerating joint structures.

There are also significant adverse side effects.

A recent licensing deal highlights significant potential commercial opportunity for PPS, as French pharmaceutical group, Servier, licensed a Phase 1 OA drug candidate for US$346 million for rights to the European region.

Paul Rennie, chief executive officer, commented:

"We are very pleased to confirm the first participant has been treated in this important clinical trial.

"Injectable PPS could be a promising, safe and effective treatment for OA with concurrent BMLs – a condition with significant unmet medical need.

"Moreover, the Servier deal for GLPG1972, a Phase 1 drug that only inhibits ADAMTS-5, illustrates the potentially significant commercial value of PPS as PPS inhibits both cartilage destroying enzymes ADAMTS-4 and ADAMTS-5."

READ NOW: Paradigm reveals outcomes from patient case studies on Osteoarthritis

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.24 AUD

ASX:PAR
Market: ASX
Market Cap: $728.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read